In our series of vlogs, Dr Stanton describes what personalised medicine means to her and her research. Emma joined Oxford Nanopore in 2020 as Clinical VP. She is also its first Head of Oxford Nanopore Diagnostics (OND). In this role, she supports its ambitions for growth in healthcare applications. Emma is excited about the opportunity to grow a diagnostics business that applies technology to health care in a targeted way. Over time, this will make a huge difference to patients and their families. Until November 2020, Emma was Director for Supplies and Innovation as part of the British government’s NHS Test and Trace response to COVID-19. Prior to this, Emma was CEO of Four Eyes Insight, Chief Partnership Officer for Beacon Health Options (Northeast USA) and CEO of Beacon in the UK. Emma has also been a Commonwealth Fund Harkness Fellow in Healthcare Policy and Practice and a Senior Associate at the Institute for Strategy and Competitiveness, both at Harvard University. Prior to this, Emma was a practicing clinician in the National Health Service (NHS). Emma holds an Executive MBA from Imperial College London, a MRCPsych from the Royal College of Psychiatrists and a Bachelor of Medicine from Southampton University.